Neurogene Net Income
| NGNE Stock | 17.38 0.38 2.24% |
As of the 14th of February 2026, Neurogene secures the Risk Adjusted Performance of (0.1), mean deviation of 3.57, and Standard Deviation of 4.71. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurogene, as well as the relationship between them. Please verify Neurogene market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Neurogene is priced some-what accurately, providing market reflects its recent price of 17.38 per share. Given that Neurogene has information ratio of (0.15), we recommend you to check Neurogene's last-minute market performance to make sure the company can sustain itself at a future point.
Neurogene Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -67.6 M | -64.2 M | |
| Net Loss | -67.6 M | -71 M | |
| Net Loss | (4.92) | (4.67) | |
| Net Income Per E B T | 0.89 | 0.80 |
Neurogene | Net Income | Build AI portfolio with Neurogene Stock |
Analyzing Neurogene's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Neurogene's current valuation and future prospects.
Latest Neurogene's Net Income Growth Pattern
Below is the plot of the Net Income of Neurogene over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Neurogene financial statement analysis. It represents the amount of money remaining after all of Neurogene operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Neurogene's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurogene's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (75.14 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Neurogene Net Income Regression Statistics
| Arithmetic Mean | (38,451,328) | |
| Coefficient Of Variation | (59.40) | |
| Mean Deviation | 19,199,226 | |
| Median | (36,317,000) | |
| Standard Deviation | 22,840,212 | |
| Sample Variance | 521.7T | |
| Range | 67.4M | |
| R-Value | (0.86) | |
| Mean Square Error | 140.5T | |
| R-Squared | 0.75 | |
| Slope | (3,910,674) | |
| Total Sum of Squares | 8346.8T |
Neurogene Net Income History
Other Fundumenentals of Neurogene
Neurogene Net Income component correlations
Neurogene Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurogene is extremely important. It helps to project a fair market value of Neurogene Stock properly, considering its historical fundamentals such as Net Income. Since Neurogene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurogene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurogene's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Neurogene diversify its offerings? Factors like these will boost the valuation of Neurogene. Anticipated expansion of Neurogene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Neurogene requires distinguishing between market price and book value, where the latter reflects Neurogene's accounting equity. The concept of intrinsic value - what Neurogene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neurogene's price substantially above or below its fundamental value.
It's important to distinguish between Neurogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neurogene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Neurogene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurogene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurogene.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Neurogene on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Neurogene or generate 0.0% return on investment in Neurogene over 90 days. Neurogene is related to or competes with Lineage Cell, Ocugen, Fulcrum Therapeutics, Autolus Therapeutics, ADC Therapeutics, Benitec Biopharma, and Solid Biosciences. Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. More
Neurogene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurogene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurogene upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (6.83) | |||
| Potential Upside | 6.59 |
Neurogene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurogene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurogene's standard deviation. In reality, there are many statistical measures that can use Neurogene historical prices to predict the future Neurogene's volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.29) |
Neurogene February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 3.57 | |||
| Coefficient Of Variation | (753.02) | |||
| Standard Deviation | 4.71 | |||
| Variance | 22.15 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (6.83) | |||
| Potential Upside | 6.59 | |||
| Skewness | (0.22) | |||
| Kurtosis | 1.35 |
Neurogene Backtested Returns
Neurogene has Sharpe Ratio of -0.0855, which conveys that the firm had a -0.0855 % return per unit of risk over the last 3 months. Neurogene exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurogene's Mean Deviation of 3.57, risk adjusted performance of (0.1), and Standard Deviation of 4.71 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 2.18, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. At this point, Neurogene has a negative expected return of -0.34%. Please make sure to verify Neurogene's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Neurogene performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Neurogene has poor predictability. Overlapping area represents the amount of predictability between Neurogene time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurogene price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Neurogene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | -0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 1.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neurogene Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neurogene reported net income of (75.14 Million). This is 122.02% lower than that of the Biotechnology sector and 207.28% lower than that of the Health Care industry. The net income for all United States stocks is 113.16% higher than that of the company.
Neurogene Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurogene's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurogene could also be used in its relative valuation, which is a method of valuing Neurogene by comparing valuation metrics of similar companies.Neurogene is currently under evaluation in net income category among its peers.
Neurogene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurogene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurogene's managers, analysts, and investors.Environmental | Governance | Social |
Neurogene Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Shares Owned By Insiders | 8.54 % | ||||
| Shares Owned By Institutions | 91.46 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Book | 0.98 X | ||||
| Price To Sales | 313.77 X | ||||
| Revenue | 925 K | ||||
| Gross Profit | (69.72 M) | ||||
| EBITDA | (71.89 M) | ||||
| Net Income | (75.14 M) | ||||
| Total Debt | 12.43 M | ||||
| Book Value Per Share | 17.97 X | ||||
| Cash Flow From Operations | (70.6 M) | ||||
| Short Ratio | 23.37 X | ||||
| Earnings Per Share | (4.10) X | ||||
| Target Price | 57.2 | ||||
| Number Of Employees | 107 | ||||
| Beta | 2.04 | ||||
| Market Capitalization | 263.33 M | ||||
| Total Asset | 335.73 M | ||||
| Retained Earnings | (262.3 M) | ||||
| Working Capital | 300.77 M | ||||
| Net Asset | 335.73 M |
About Neurogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Neurogene diversify its offerings? Factors like these will boost the valuation of Neurogene. Anticipated expansion of Neurogene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Neurogene requires distinguishing between market price and book value, where the latter reflects Neurogene's accounting equity. The concept of intrinsic value - what Neurogene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neurogene's price substantially above or below its fundamental value.
It's important to distinguish between Neurogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neurogene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.